Posted by Michael Wonder on 15 May 2026
INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease
14 May 2025 - INmune Bio today announced that the US FDA has granted fast track designation to XPro (pegipanermin), the company's first in class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease.
The designation specifically covers XPro for treatment of early Alzheimer's disease encompassing both mild cognitive impairment due to Alzheimer's disease and mild Alzheimer’s disease dementia, which represents a large and growing population.
